Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?

Read full text Summarise with VIRAT
Authors: Leonel Varela Cagetti, Julia Gilhodes, Marjorie Ferrè, Marguerite Tyran, Morgan Guénolé, Jean Phillippe Ratone, Fabrice Caillol, Flora Poizat, Bernard Lelong, Cécile de Chaisemartin, Hélène Meillat, Christelle de la Fouchardière
+2 more Naji Salem, Agnes Richard Tallet
Cited by: 0
References: 53

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Purpose:To analyze and compare the clinical outcomes of boost modality choice after external beam radiation therapy (EBRT) or chemoradiotherapy (CRT) for anal canal cancers (ACC).Material and methods: 162 patients with ACC were treated in our institution with two different boost modalities: EBRT boost (EBRTb) or high-dose-rate (HDR) interstitial brachytherapy boost (ISBT).Local relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS), colostomy-free survival (CFS), and toxicity rates were analyzed.Results: With a median follow-up (FU) of 66 months, thirteen (8%) local recurrences were reported, six in the ISBT and seven in the EBRTb groups.The 5-year LRFS rate for the entire cohort was 87% (80-92%), without differences in both groups: 88% in ISBT vs. 86% in EBRTb group (p = 0.7).The 5-year DFS, OS, and CFS rates for the overall population were 84% (78-89%), 93% (88-96%), and 92% (88-95%), respectively, without significant differences between ISBT and EBRTb groups.Multivariate analysis for gastrointestinal (GI) toxicity found a non-significant tendency between EBRTb and GI toxicity grade ≥ 2: odds ratio (OR) = 1.82 (0.88-3.78), p = 0.1060.Univariate analysis for fecal incontinence revealed that EBRTb was significantly associated with fecal incontinence grade ≥ 2 (p = 0.0005), and this tendency was confirmed in the multivariate analysis (p = 0.0012).Sensitivity analysis, excluding patients with theoretical brachytherapy contraindications, confirmed these results.Univariate and multivariate assessments found ISBT as an independent prognosis factor for better sphincter function: OR = 5.44 (1.57-18.91),p = 0.0077.Conclusions: CRT provide excellent rates of tumor control and colostomy-free survival.Compared with EBRTb, interstitial brachytherapy boost demonstrates a favorable profile in GI toxicity, with a low impact on fecal incontinence.

Fields of Study & Subjects

Colorectal and Anal Carcinomas Colorectal Cancer Surgical Treatments Esophageal Cancer Research and Treatment

Publication details

Journal / source
Journal of Contemporary Brachytherapy
Volume
18
Issue
1
Pages
48–57
Publication date
1 March 2026
Language
EN